New research suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt traditional lifestyle regimens.
Published data in a major health publication shows that while obese individuals can lose about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such drugs must be cognizant of the potential of rapid rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain means a reversion to original mass within about a year and a half.
Comparing Approaches
The research, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
The team point out that individuals who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Experts suggest the way of the injections accounts for the accelerated regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
Health authorities suggest the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, due to the high risk of relapse, the therapy is often long-term.
This opinion is supported by drug manufacturers, who say that the findings "emphasize the persistent nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
Users who have come off the jabs report a sudden return of cravings.
"It felt as if a switch activating and you're instantly ravenous," recalled an individual.
This difficulty is exacerbated if patients have not adopted sustainable dietary or behavioural modifications during treatment.
Growing Interest
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, experts stress that while these medications are powerful tools for weight loss, they are not a magic fix and maintained weight loss hinges on integrated lifestyle management.
